Table of Contents
Chapter 1. Methodology and Scope
1.1 Market Segmentation and Scope
1.1.1 Segment Definitions
1.1.1.1 Test Type
1.1.1.1 Sample Type
1.1.1.1 Collection Site
1.2 Regional Scope
1.3 Estimates And Forecast Timeline
1.4 Objectives
1.4.1 Objective – 1
1.4.2 Objective – 2
1.4.3 Objective – 3
1.5 Research Methodology
1.6 Information Procurement
1.6.1 Purchased Database
1.6.2 Gvr’s Internal Database
1.6.3 Secondary Sources
1.6.4 Primary Research
1.7 Information Or Data Analysis
1.7.1 Data Analysis Models
1.8 Market Formulation & Validation
1.9 Model Details
1.9.1 Commodity Flow Analysis
1.10 List of Secondary Sources
1.11 List of Abbreviations
Chapter 2. Executive Summary
2.1. Market Snapshot
2.2. Technology Snapshot
2.3. Competitive Landscape Snapshot
Chapter 3. Market Variables, Trends, & Scope
3.1. Market Segmentation and Scope
3.2. Market Lineage Outlook
3.2.1. Parent Market Outlook
3.2.2. Related/Ancillary Market Outlook
3.3. Market Trends and Outlook
3.4. Market Dynamics
3.4.1. Increasing demand for diagnostic tools in malaria-endemic countries
3.4.2. Development of technologically advanced and efficient diagnostics
3.4.3. Market players and private investors to curb the prevalence of malaria
3.5. Market Restraint Analysis
3.5.1. Increasing number of countries in the malaria elimination phase
3.5.2. Demand for low-cost malaria diagnostic tests
3.6. Business Environment Analysis
3.6.1. SWOT Analysis; By Factor (Political & Legal, Economic And Technological)
3.6.2. Porter’s Five Forces Analysis
3.7. COVID-19 Impact Analysis
Chapter 4. Malaria Diagnostics Market – Segment Analysis, By Technology, 2018 – 2030 (USD Million)
4.1. Malaria Diagnostics Market: Technology Movement Analysis
4.2. Microscopy
4.2.1. Microscopy Market, 2018 – 2030 (USD Million)
4.3. Rapid Diagnostic Tests (RDTs)
4.3.1. Rapid Diagnostic Tests (RDTs) Market, 2018 – 2030 (USD Million)
4.4. Molecular Diagnostic Tests
4.4.1. Molecular Diagnostic Tests Market, 2018 – 2030 (USD Million)
4.4.2. Conventional PCR
4.4.2.1. Conventional PCR Market, 2018 – 2030 (USD Million
4.4.3. Real-Time PCR (qPCR or quantitative PCR)
4.4.3.1. Real-Time PCR (qPCR or quantitative PCR) Market, 2018 – 2030 (USD Million)
Chapter 5. Malaria Diagnostics Market – Segment Analysis, By End-use, 2018 – 2030 (USD Million)
5.1. Malaria Diagnostics Market: End-use Movement Analysis
5.2. Clinics
5.2.1. Clinics Market, 2018 – 2030 (USD Million)
5.3. Hospitals
5.3.1. Hospitals Market, 2018 – 2030 (USD Million)
5.4. Diagnostic Centers
5.4.1. Diagnostic Centers Market, 2018 – 2030 (USD Million)
Chapter 6. Regional Business Analysis
6.1. Malaria Diagnostics Market Share By Region, 2022 & 2030
6.2. Africa
6.2.1. SWOT Analysis
6.2.2. Africa Malaria Diagnostics Market, 2018 – 2030 (USD Million)
6.2.3. Nigeria
6.2.3.1. Key Country Dynamics
6.2.3.2. Target Disease Prevalence
6.2.3.3. Competitive Scenario
6.2.3.4. Regulatory Framework
6.2.3.5. Reimbursement Scenario
6.2.3.6. Nigeria Malaria Diagnostics Market, 2018-2030 (USD MILLION)
6.2.4. Democratic Republic of Congo
6.2.4.1. Key Country Dynamics
6.2.4.2. Target Disease Prevalence
6.2.4.3. Competitive Scenario
6.2.4.4. Regulatory Framework
6.2.4.5. Reimbursement Scenario
6.2.4.6. Democratic Republic of Congo Malaria Diagnostics Market, 2018 – 2030 (USD Million)
6.2.5. Uganda
6.2.5.1. Key Country Dynamics
6.2.5.2. Target Disease Prevalence
6.2.5.3. Competitive Scenario
6.2.5.4. Regulatory Framework
6.2.5.5. Reimbursement Scenario
6.2.5.6. Uganda Malaria Diagnostics Market, 2018 – 2030 (USD Million)
6.3. Southeast Asia
6.3.1. SWOT Analysis
6.3.2. Southeast Asia Malaria Diagnostics Market, 2018 – 2030 (USD Million)
6.3.3. India
6.3.3.1. Key Country Dynamics
6.3.3.2. Target Disease Prevalence
6.3.3.3. Competitive Scenario
6.3.3.4. Regulatory Framework
6.3.3.5. Reimbursement Scenario
6.3.3.6. India Malaria Diagnostics Market, 2018 – 2030 (USD Million)
6.3.4. Myanmar
6.3.4.1. Key Country Dynamics
6.3.4.2. Target Disease Prevalence
6.3.4.3. Competitive Scenario
6.3.4.4. Regulatory Framework
6.3.4.5. Reimbursement Scenario
6.3.4.6. Myanmar Malaria Diagnostics Market, 2018 – 2030 (USD Million)
6.3.5. Indonesia
6.3.5.1. Key Country Dynamics
6.3.5.2. Target Disease Prevalence
6.3.5.3. Competitive Scenario
6.3.5.4. Regulatory Framework
6.3.5.5. Reimbursement Scenario
6.3.5.6. Indonesia Malaria Diagnostics Market, 2018 – 2030 (USD Million)
6.4. Eastern Mediterranean Asia
6.4.1. SWOT Analysis
6.4.2. Eastern Mediterranean Asia Malaria Diagnostics Market, 2018 – 2030 (USD Million)
6.4.3. Saudi Arabia
6.4.3.1. Key Country Dynamics
6.4.3.2. Target Disease Prevalence
6.4.3.3. Competitive Scenario
6.4.3.4. Regulatory Framework
6.4.3.5. Reimbursement Scenario
6.4.3.6. Saudi Arabia Malaria Diagnostics Market, 2018 – 2030 (USD Million)
6.4.4. Pakistan
6.4.4.1. Key Country Dynamics
6.4.4.2. Target Disease Prevalence
6.4.4.3. Competitive Scenario
6.4.4.4. Regulatory Framework
6.4.4.5. Reimbursement Scenario
6.4.4.6. Pakistan Malaria Diagnostics Market, 2018 – 2030 (USD Million)
6.5. Western Pacific
6.5.1. SWOT Analysis
6.5.2. Western Pacific Malaria Diagnostics Market, 2018 – 2030 (USD Million)
6.5.3. China
6.5.3.1. Key Country Dynamics
6.5.3.2. Target Disease Prevalence
6.5.3.3. Competitive Scenario
6.5.3.4. Regulatory Framework
6.5.3.5. Reimbursement Scenario
6.5.3.6. China Malaria Diagnostics Market, 2018 – 2030 (USD Million)
6.5.4. Papua New Guinea
6.5.4.1. Key Country Dynamics
6.5.4.2. Target Disease Prevalence
6.5.4.3. Competitive Scenario
6.5.4.4. Regulatory Framework
6.5.4.5. Reimbursement Scenario
6.5.4.6. Papua New Guinea Diagnostics Market, 2018 – 2030 (USD Million)
6.5.5. Cambodia
6.5.5.1. Key Country Dynamics
6.5.5.2. Target Disease Prevalence
6.5.5.3. Competitive Scenario
6.5.5.4. Regulatory Framework
6.5.5.5. Reimbursement Scenario
6.5.5.6. Cambodia Malaria Diagnostics Market, 2018 – 2030 (USD Million)
6.6. Americas
6.6.1. SWOT Analysis
6.6.2. Americas Malaria Diagnostics Market, 2018 – 2030 (USD Million)
6.6.3. Brazil
6.6.3.1. Key Country Dynamics
6.6.3.2. Target Disease Prevalence
6.6.3.3. Competitive Scenario
6.6.3.4. Regulatory Framework
6.6.3.5. Reimbursement Scenario
6.6.3.6. Brazil Malaria Diagnostics Market, 2018 – 2030 (USD Million)
6.6.4. Venezuela
6.6.4.1. Key Country Dynamics
6.6.4.2. Target Disease Prevalence
6.6.4.3. Competitive Scenario
6.6.4.4. Regulatory Framework
6.6.4.5. Reimbursement Scenario
6.6.4.6. Venezuela Malaria Diagnostics Market, 2018 – 2030 (USD Million)
6.6.5. Colombia
6.6.5.1. Key Country Dynamics
6.6.5.2. Target Disease Prevalence
6.6.5.3. Competitive Scenario
6.6.5.4. Regulatory Framework
6.6.5.5. Reimbursement Scenario
6.6.5.6. Colombia Malaria Diagnostics Market, 2018 – 2030 (USD Million)
6.7. Europe
6.7.1. SWOT Analysis
6.7.2. Europe Malaria Diagnostics Market, 2018 – 2030 (USD Million)
6.7.3. Germany
6.7.3.1. Key Country Dynamics
6.7.3.2. Target Disease Prevalence
6.7.3.3. Competitive Scenario
6.7.3.4. Regulatory Framework
6.7.3.5. Reimbursement Scenario
6.7.3.6. Germany Malaria Diagnostics Market, 2018 – 2030 (USD Million)
6.7.4. UK
6.7.4.1. Key Country Dynamics
6.7.4.2. Target Disease Prevalence
6.7.4.3. Competitive Scenario
6.7.4.4. Regulatory Framework
6.7.4.5. Reimbursement Scenario
6.7.4.6. UK Malaria Diagnostics Market, 2018 – 2030 (USD Million)
6.7.5. France
6.7.5.1. Key Country Dynamics
6.7.5.2. Target Disease Prevalence
6.7.5.3. Competitive Scenario
6.7.5.4. Regulatory Framework
6.7.5.5. Reimbursement Scenario
6.7.5.6. France Malaria Diagnostics Market, 2018 – 2030 (USD Million)
6.7.6. Turkey
6.7.6.1. Key Country Dynamics
6.7.6.2. Target Disease Prevalence
6.7.6.3. Competitive Scenario
6.7.6.4. Regulatory Framework
6.7.6.5. Reimbursement Scenario
6.7.6.6. Turkey Malaria Diagnostics Market, 2018 – 2030 (USD Million)
Chapter 7. Competitive Landscape
7.1 Company Categorization
7.2 Strategy Mapping
7.2.1 New Product Launch
7.2.2 Partnerships
7.2.3 Acquisition
7.2.4 Collaboration
7.2.5 Funding
7.3 Key Company Market Share Analysis, 2022
7.4 Company Profiles
7.4.1 Access Bio., Inc.
7.4.1.1 Company overview
7.4.1.2 Financial performance
7.4.1.3 Product benchmarking
7.4.1.4 Strategic Initiatives
7.4.2 Abbott Laboratories
7.4.2.1 Company overview
7.4.2.2 Financial performance
7.4.2.3 Product benchmarking
7.4.2.4 Strategic Initiatives
7.4.3 Premier Medical Corporation Pvt. Ltd.
7.4.3.1 Company overview
7.4.3.2 Financial performance
7.4.3.3 Product benchmarking
7.4.3.4 Strategic Initiatives
7.4.4 Sysmex Partec GmbH
7.4.4.1 Company overview
7.4.4.2 Product benchmarking
7.4.4.3 Strategic Initiatives
7.4.5 bioMérieux
7.4.5.1 Company overview
7.4.5.2 Financial performance
7.4.5.3 Product benchmarking
7.4.5.4 Strategic Initiatives
7.4.6 Beckman Coulter, Inc.
7.4.6.1 Company overview
7.4.6.2 Financial performance
7.4.6.3 Product benchmarking
7.4.6.4 Strategic Initiatives
7.4.7 Siemens Healthineers
7.4.7.1 Company overview
7.4.7.2 Financial performance
7.4.7.3 Product benchmarking
7.4.7.4 Strategic Initiatives
7.4.8 Leica Microsystems GmbH
7.4.8.1 Company overview
7.4.8.2 Financial performance
7.4.8.3 Product benchmarking
7.4.8.4 Strategic Initiatives
7.4.9 Nikon Corporation
7.4.9.1 Company overview
7.4.9.2 Financial performance
7.4.9.3 Product benchmarking
7.4.9.4 Strategic Initiatives
7.4.10 Olympus Corporation
7.4.10.1 Company overview
7.4.10.2 Financial performance
7.4.10.3 Product benchmarking
7.4.10.4 Strategic Initiatives
7.4.11 Bio-Rad Laboratories, Inc.
7.4.11.1 Company overview
7.4.11.2 Financial performance
7.4.11.3 Product benchmarking
7.4.11.4 Strategic Initiatives
Chapter 8. KOL Recommendations/ Conclusion
❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer